Rachel M. Lee

Rachel M. Lee

Auto-generated profile, based on publicly available information

Rachel M. Lee

Department of Psychology, Faculty of Science, Memorial University, St. John’s, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2023 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
RLRachel M. Lee
Rachel M. Lee
JDJennifer Donnan
Jennifer Donnan
NHNick Harris
Nick Harris
SGSheila Nadine Garland
Sheila Nadine Garland

10 May 2025 in Sleep Science and Practice
Verified
Journal Article
Open access
PDF file
KGKrista M. Greeley
Krista M. Greeley
RLRachel M. Lee
Rachel M. Lee
JTJoshua Tulk
Joshua Tulk
SHScott V. Harding
Scott V. Harding
YYYanqing Yi
Yanqing Yi
SGSheila Nadine Garland
Sheila Nadine Garland
Sleep disturbances are one of the biggest barriers to resuming normal functioning following cancer treatment. Cognitive behavioral therapy for insomnia (CBT-I) has demonstrated efficacy in cancer survivors but few studies have recorded adverse events (AEs) that occur during treatment. The purpose of this study was to report the prevalence, severity, and attribution of AEs during CBT-I with cancer survivors. Cancer survivors from Atlantic Canada with insomnia and comorbid cognitive impairment were recruited to participate in a randomized controlled trial of CBT-I. Participants reported the prevalence, severity, and attribution of AEs at mid-treatment (4 weeks) and post-treatment (8 weeks). The likeliness of AEs being related to treatment was also rated by an independent clinician. Of the 122 cancer survivors who completed treatment (Mage = 60.3, 77.9% women), 72 reported a total of 197 AEs. At mid-treatment, participants reported 113 AEs, but only 11 were rated as being attributed to the intervention. At post-treatment, participants did not report any AEs attributed to the intervention. An independent rater attributed more AEs to the treatment than the participants at both time points (4 weeks: 16 vs. 11, 8 weeks: 1 vs. 0). Gender (p = .014) and pre-treatment anxiety (p < .001) were associated with reporting an AE. CBT-I is a safe treatment that is well-tolerated by cancer survivors. The majority of participants did not experience AEs that could be attributed to the treatment. Clinicians should continue to recommend CBT-I as the first-line treatment for cancer survivors experiencing insomnia symptoms. This study is a secondary analysis of a randomized controlled trial titled ‘Addressing Cancer Treatment-Related Insomnia Online in Atlantic Canada (ACTION) study’ ( https://www.clinicaltrials.gov/search?cond=NCT04026048 identifier: NCT04026048).

18 March 2024 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
RLRachel M. Lee
Rachel M. Lee
JRJoshua Rash
Joshua Rash
MSMelanie Seal
Melanie Seal
JMJoy McCarthy
Joy McCarthy
SGSheila Nadine Garland
Sheila Nadine Garland

23 September 2025 in JMIR Cancer
Verified
Journal Article
Open access
SGSheila Nadine Garland
Sheila Nadine Garland
SKSamlau Kutana
Samlau Kutana
KPKatherine-Ann Piedalue
Katherine-Ann Piedalue
RLRachel Lee
Rachel Lee
JRJoshua Rash
Joshua Rash
GCGregory Cerallo
Gregory Cerallo
Background: Insomnia affects the quality of life and health outcomes of cancer survivors. Cognitive behavioral therapy for insomnia (CBT-I) is an effective treatment for insomnia among cancer survivors, but it is not readily accessible due to the limited number of trained providers and the difficulties in providing care across wide geographical areas. Mobile health (mHealth) technologies represent a promising solution; however, these technologies are not tailored to the unique needs of cancer survivors. Objective: This study aimed to understand the needs and preferences of cancer survivors and test the usability of an evidence-based CBT-I smartphone app called iCANSleep that will be tailored and accessible to cancer survivors. Methods: A user-centered design (UCD) approach was applied, and cancer survivors were actively engaged in the app’s design, usability testing, and prototype refinement. In phase 1, semistructured interviews were conducted with a purposive sample of cancer survivors (n=20) to inform the design of the app and its content. In phase 2, iterative low- (n=8) and high-fidelity (n=7) usability testing was conducted with participants until no further recommendations for change were suggested. Results: Users suggested several defining characteristics, features, and desired functionalities, including a user-friendly and evidence-based design. They saw increased accessibility and simplicity as advantages of a mobile app but expressed some concerns about data security and losing the accountability that comes with in-person treatment. User testing highlighted the preference for images of real people and diverse stories over graphics and animated videos, and offered suggestions for enhanced navigation. The first iteration of the app was developed using the information gained during the needs assessment and usability testing. Feedback was integrated into the final prototype of the iCANSleep app, which will be tested for feasibility, acceptability, and efficacy. Conclusions: Cancer survivors desire an insomnia treatment app that is simple, user-friendly, evidence-based, convenient, and secure. The iCANSleep app represents the merging of mHealth principles and best practices with evidence-based insomnia care, allowing for an intervention with minimal access barriers related to cost, geography, and provider availability. Feasibility, acceptability, and efficacy of the intervention will be maximized by following a UCD framework involving the engagement of end users at every design stage.

7 October 2026 in Current Sleep Medicine Reports
Verified
Journal Article
Closed access
PDF file
RLRachel M. Lee
Rachel M. Lee
SGSheila Nadine Garland
Sheila Nadine Garland

28 May 2024 in Behavioral Sleep Medicine
Verified
Journal Article
Closed access
RLRachel M. Lee
Rachel M. Lee
JDJennifer Donnan
Jennifer Donnan
NHNick Harris
Nick Harris
SGSheila Nadine Garland
Sheila Nadine Garland
Poor sleep is a common side effect of cancer. Cannabis is increasingly used to manage cancer treatment-related symptoms, including sleep. This study investigated factors related to cannabis use for sleep among Canadian cancer survivors. Adult Canadian cancer survivors (N = 940) were recruited via the Angus Reid Institute and completed an online, cross-sectional survey. Univariate and multiple binomial logistic regression models identified factors associated with cannabis use for sleep. Of the participants (Mage = 64.5 yrs; Women = 51.1%; White = 92.9%), 25.1% (n = 236) currently use cannabis for sleep. Participants were at greater odds of using cannabis for sleep if they identified as a gender other than man or woman (AOR = 11.132), were diagnosed with multiple medical conditions (2:AOR = 1.988; 3+:AOR = 1.902), two psychological conditions (AOR = 2.171), multiple sleep disorders (AOR = 2.338), insomnia (AOR = 1.942), bone (AOR = 6.535), gastrointestinal (AOR = 4.307), genitourinary (AOR = 2.586), hematological (AOR = 4.739), or an unlisted cancer (AOR = 3.470), received hormone therapy only (AOR = 3.054), drink heavily (AOR = 2.748), or had mild insomnia (AOR = 1.828). Older participants (AOR=.972) and those with sleep apnea were less likely to use cannabis for sleep (AOR=.560). Given its prevalence, research is needed to understand how factors associated with cannabis use as a sleep aid among Canadian cancer survivors may influence its use and effectiveness and whether these factors are barriers to accessing evidence-based treatments.